CRA’s Life Sciences Practice was retained by a biotechnology company to perform a valuation of its gene editing patent portfolio, and to provide recommendations regarding potential licensing agreements with other companies. CRA developed a valuation model based on publicly available information relating to market opportunities, potential sales, and various risk factors for products in the field of human therapeutics. In addition to assisting the company in assessing the market potential for the use of the relevant patents in the fields of agriculture and research tools. CRA provided recommendations regarding the optimal royalty structure to include in potential future licensing agreements.
Chris Bakewell recognized in Top 25 Patent Damages Experts for 2025
CRA is proud to announce that Chris Bakewell has been recognized as one of the Certified Patent Valuation Analyst’s Top 25 Patent Damages Experts for 2025. We...